Audentes Therapeutics

     Drug: AT466

     Approach: AAV-antisense

     Status: Preclinical.  Plans to file IND in 2020.

     Company website explaining AT466.

     April 8, 2019 Press Release announcing collaboration with Nationwide Children's Hospital